Hepatic clearance, but not gut availability, of erythromycin is altered in patients with end-stage renal disease.
about
A Synopsis of Clinical Pharmacokinetic Alterations in Advanced CKDPharmacokinetics of tedizolid in subjects with renal or hepatic impairment.Clinical manifestation of macrolide antibiotic toxicity in CKD and dialysis patients.Drug Transporters and Na+/H+ Exchange Regulatory Factor PSD-95/Drosophila Discs Large/ZO-1 ProteinsEffects of uremic toxins on transport and metabolism of different biopharmaceutics drug disposition classification system xenobioticsModeling and predicting drug pharmacokinetics in patients with renal impairment.Current understanding of drug disposition in kidney disease.The role of BCS (biopharmaceutics classification system) and BDDCS (biopharmaceutics drug disposition classification system) in drug developmentEffects of chronic kidney disease and uremia on hepatic drug metabolism and transport.Pharmacokinetic considerations in chronic kidney disease and patients requiring dialysis.BDDCS, the Rule of 5 and drugability.Effects of decreased vitamin D and accumulated uremic toxin on human CYP3A4 activity in patients with end-stage renal diseasePossibility of decrease in CYP1A2 function in patients with end-stage renal disease.Regulatory perspectives on designing pharmacokinetic studies and optimizing labeling recommendations for patients with chronic kidney disease.Inhibition of human drug-metabolising cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in vitro by uremic toxins.Cooperative inhibitory effects of uremic toxins and other serum components on OATP1B1-mediated transport of SN-38.Improved Predictions of Drug-Drug Interactions Mediated by Time-Dependent Inhibition of CYP3A.The Role of the Kidney in Drug Elimination: Transport, Metabolism, and the Impact of Kidney Disease on Drug Clearance.
P2860
Q28087621-90C836D1-8A82-45D5-B27E-412BC90A73C5Q34596658-F72EF8C4-612B-4904-BCD1-99A1172AB493Q35310541-75208A21-8A25-4089-8D9B-BCABDBFAA131Q35795744-5D17F399-9C8E-4ADD-844D-8E9696F6F78EQ36634986-C13FC971-D211-49E5-BA84-49EC57D2225CQ37960638-1B8E8BAF-C2C8-4401-9D46-A24B66417759Q37974644-E558B1D0-25B2-4C11-B3AE-189544080B3DQ38059421-CD23274A-3DEC-4300-91BD-0029FA591B72Q38153196-873A5851-DC55-4134-BB4F-5DD1451135A4Q38222867-214A52D2-DAE2-4163-8844-F54F1ADEA672Q38835159-D30D5328-987A-4226-BA42-780DBD056821Q39107147-0A9C7AD8-DCEF-4E16-9520-B338A884C9A0Q44095990-084575E8-EC7D-40E7-A622-B6A25873BD93Q45815953-8ABB77F3-6493-4643-BC83-15A31EE7E0EAQ47853973-943F5043-CEED-4C6A-98BC-77571C09161DQ47925309-A279445E-8CA6-421F-B9A2-0AA4FF81C7E6Q52334679-58080247-825F-4C0E-8CA3-4707942E36B3Q53233045-3506C9A0-15CF-4F8A-A880-E7C0364527C9
P2860
Hepatic clearance, but not gut availability, of erythromycin is altered in patients with end-stage renal disease.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Hepatic clearance, but not gut ...... with end-stage renal disease.
@ast
Hepatic clearance, but not gut ...... with end-stage renal disease.
@en
type
label
Hepatic clearance, but not gut ...... with end-stage renal disease.
@ast
Hepatic clearance, but not gut ...... with end-stage renal disease.
@en
prefLabel
Hepatic clearance, but not gut ...... with end-stage renal disease.
@ast
Hepatic clearance, but not gut ...... with end-stage renal disease.
@en
P2093
P2860
P356
P1476
Hepatic clearance, but not gut ...... with end-stage renal disease.
@en
P2093
P2860
P304
P356
10.1038/CLPT.2009.247
P407
P577
2010-01-20T00:00:00Z